Displaying results 1 - 10 of 10 for healthcare reform in the united states. Subscribe to this search
DUBLIN, Ireland & YOQNEAM, Israel--(BUSINESS WIRE)--Dec 8, 2013--Covidien plc (NYSE: COV) and Given Imaging Ltd. (Nasdaq: GIVN) today announced a definitive agreement under which Covidien will acquire all of the outstanding shares of Given Imaging for $30.00 per share in cash, for a total of approximately $860 million, net of cash and investments acquired. This transaction provides Covidien additional scale and scope to serve the multibillion dollar global gastrointestinal (GI) market and supports the Company’s strategy to comprehensively address key global specialties and procedures.
NEW YORK--(BUSINESS WIRE)--Dec 4, 2013--Multi Packaging Solutions, Inc. (“MPS”) announced today that it is seeking consent to proposed amendments, as revised by new proposed amendments, to certain provisions of the indenture (the “Indenture”) governing its 8.500% Senior Notes due 2021 (the “Notes”), as well as an increased consent fee as set forth below. The new proposed amendments are in addition to and supplement the proposed amendments in the previously announced consent solicitation related to the Notes.
NEW YORK--(BUSINESS WIRE)--Nov 21, 2013--Multi Packaging Solutions, Inc. (“MPS”) announced today that, in connection with the previously announced entry into the combination agreement with Chesapeake Services Limited (“Chesapeake”), MPS is soliciting consents from holders of its 8.500% Senior Notes due 2021 (the “Notes”) to approve amendments (the “Proposed Amendments”) to certain provisions of the indenture (the “Indenture”) governing the Notes.
DEERFIELD, Ill. & SEATTLE--(BUSINESS WIRE)--Nov 15, 2013--Baxter International Inc. (NYSE:BAX) and Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today jointly announced that they have entered into an exclusive worldwide licensing agreement to develop and commercialize pacritinib. Pacritinib is a novel investigational JAK2/FLT3 inhibitor with activity against genetic mutations linked to myelofibrosis, leukemia and certain solid tumors. Pacritinib is currently in Phase III development for patients with myelofibrosis, a chronic malignant bone marrow disorder.
CHARLESTON, S.C.--(BUSINESS WIRE)--Nov 13, 2013--Blackbaud, Inc. (Nasdaq: BLKB ), a leading global provider of software and services designed for nonprofits, today announced that Michael P. Gianoni has been named president and chief executive officer, effective January 13, 2014. Gianoni will also join the Blackbaud Board of Directors, effective upon becoming chief executive officer. Anthony Boor, who has served as interim president and chief executive officer since August 31, 2013, will maintain that role until January 13, 2014, after which he will continue to serve as chief financial officer and senior vice president, finance and administration.
WASHINGTON (AP) — Medicaid is the underdog of government health care programs. But it's turning into a rare early success story for President Barack Obama's technologically challenged health overhaul.
SARASOTA - The U.S. Department of Health and Human Services released a report Wednesday on premium costs within the new, online health insurance exchange.
HARTFORD, Conn.--(BUSINESS WIRE)--Jun 11, 2013--While the majority of small business owners generally feel successful with how their businesses are operating, they are becoming increasingly more conservative with the overall level of risk they are taking with their business, according to , released today.
Olympia Jean Snowe McKernan is the senior United States Senator from Maine. She is a Republican and a leading moderate within the party. Snowe has become widely known for her ability to influence the outcome of close votes, including whether to end filibusters.
The United States Senate Committee on Finance approved a proposal to reform health care on Tuesday, clearing it to move forward. The bill passed by a 14-9 vote, gaining support from the committee's thirteen Democrats, and one Republican.